Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 19/20 | 0.63 |
| ▸ | FAAH | O00519 | 4/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973425 | 1.00 | EPHX2 (0.63) | EPHX2FAAHKDM1AMAOBRAF1 | |
| SCHEMBL10148485 | 0.90 | EPHX2 (0.50) | EPHX2FAAHKDM1AMAOBRAF1 | |
| SCHEMBL31114524 | 0.90 | EPHX2 (0.50) | EPHX2FAAHKDM1AMAOBRAF1 | |
| SCHEMBL31114455 | 0.89 | EPHX2 (0.59) | EPHX2FAAHKDM1AMAOBRAF1 | |
| SCHEMBL24078617 | 0.88 | EPHX2 (0.48) | EPHX2FAAHKDM1AMAOB | |
| SCHEMBL29126597 | 0.88 | EPHX2 (0.48) | EPHX2FAAHKDM1AMAOB | |
| SCHEMBL2647959 | 0.88 | KDM1A (0.62) | EPHX2FAAHKDM1AMAOB | |
| SCHEMBL14647010 | 0.88 | KDM1A (0.62) | EPHX2FAAHKDM1AMAOB | |
| SCHEMBL25060070 | 0.87 | EPHX2 (0.54) | EPHX2FAAHKDM1AMAOB | |
| SCHEMBL31669351 | 0.86 | EPHX2 (0.55) | EPHX2FAAHKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | EPHX2 1718/4885FAAH 1026/4885KDM1A 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.